Impact factor enshittification: Reflections on metrics, incentives and scientific publishing [0.03%]
影响因子变劣化：关于科研评价、激励和科技期刊出版的思考
Norberto C Chávez-Tapia,Agustín Albillos Martínez,Stephen L Chan et al.
Norberto C Chávez-Tapia et al.
Impact of adding statins to non-selective beta-blockers in cirrhosis with portal hypertension: a systematic review and meta-analysis of randomized controlled trials [0.03%]
他汀类药物联合非选择性β受体阻滞剂治疗门脉高压的系统评价和meta分析
Qingping Wu,Yifei Yang,Qi Wu et al.
Qingping Wu et al.
Introduction and objectives: Despite non-selective beta-blockers (NSBBs), patients with cirrhosis and portal hypertension (PH) remain at substantial risk of death. Statins may improve intrahepatic microcirculation and pot...
Pragmatism should not eclipse validation in expanded HBV management for Latin America: response [0.03%]
拉美地区不应以实用主义代替乙肝扩展化管理的检验：回复
Ezequiel Ridruejo,Mario Pessoa,Nelia Hernandez
Ezequiel Ridruejo
Alcohol-associated liver disease in Asian Americans: the case for disaggregated analysis [0.03%]
亚洲美国人的酒精相关性肝病：分开分析的必要性
Muhammad Ali Tariq,Madiha Khan,Aiman Fatima Malik
Muhammad Ali Tariq
None. Keywords: Alcohol-associated liver disease; Asian Americans; alcohol use disorder; disparities; race. ...
Asia-Pacific perspectives on the steatotic liver disease (SLD) reclassification: balancing terminology, diagnostic criteria, and implementation [0.03%]
亚太地区关于脂肪性肝病（SLD）再分类的观点：平衡术语、诊断标准和实施问题
Kuo Chao Yew,Quan Rui Tan,Bernett Lee et al.
Kuo Chao Yew et al.
Introduction and objectives: The global transition from non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD), encompassing metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic ...
Alcohol-associated Liver Disease in the MENA Region: A 16-Country Survey of Healthcare Provider Perspectives [0.03%]
中东地区酒精相关性肝病的医疗保健人员视角调查研究报告
Mohamed El-Kassas,Abeer Awad,Mohammed A Medhat et al.
Mohamed El-Kassas et al.
Introduction and objectives: Despite low alcohol consumption across most MENA countries, the burden and management challenges of alcohol-associated liver disease (ALD) remain poorly characterized. This study assessed heal...
Stem cell therapies for liver cirrhosis: a GRADE evaluation through a systematic review [0.03%]
干细胞治疗肝硬化：系统评价的GRADE证据评级分析
Manya Prasad,Priyanka Shenoy,Tushar Prabhakar et al.
Manya Prasad et al.
Introduction and Objectives Stem cell therapies have shown potential in treating liver cirrhosis and acute-on-chronic liver failure by promoting liver regeneration. However, their efficacy and safety remain uncertain due to inconsistent res...
Role of spot urine analyses in patients with cirrhosis and ascites as the single first decompensation event [0.03%]
腹水作为首次失代偿事件的肝硬化患者的尿常规检查的作用
Lorenz Balcars,Adrian Wunderbaldinger,Lucie Simonis et al.
Lorenz Balcars et al.
Introduction and objectives: Ascites is the most frequent complication in patients with cirrhosis. Although guidelines propose diuretic treatment monitoring through measuring spot urine sodium, data on its application in ...
Misclassification of UDCA treatment response in patients with primary biliary cholangitis (PBC) in the real-world setting [0.03%]
真实世界中对熊去氧胆酸治疗原发性胆汁性胆管炎(PBC)反应的误分类
Annegret Franke,Tobias Müller,Kerstin Stein et al.
Annegret Franke et al.
Introduction and objectives: Treatment response of ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC) is assessed after 12 months by Paris II criteria. In the German PBC registry, individuals were stratified...
Association between grip strength and cause-specific mortality in metabolic dysfunction-associated steatotic liver disease [0.03%]
代谢功能紊乱相关肝脂肪变性疾病患者中手握力与各病死原因之间的关系
Chao Li,Zhijia Zhao,Ying Che et al.
Chao Li et al.
Introduction and objectives: Impaired muscle strength is increasingly recognized as an integrative marker of metabolic dysfunction and adverse prognosis. This study aimed to examine the associations between grip strength ...